Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

734.81
-23.4600-3.09%
Pre-market: 741.987.17+0.98%08:05 EDT
Volume:1.04M
Turnover:770.25M
Market Cap:75.65B
PE:18.17
High:777.43
Open:766.53
Low:726.02
Close:758.27
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.30
T/O Rate:1.05%
Dividend:3.64
Dividend Rate:0.50%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.39
PE(LYR):17.71

Loading ...

Sanofi - Regeneron to Receive $1 Bln Upfront with Potential for up to an Additional $7 Bln in Future Milestone Payments

THOMSON REUTERS
·
Yesterday

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Yesterday

Regeneron Drug Halves Muscle Loss in Combination with Novo's Semaglutide in Trial

Reuters
·
Yesterday

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Regeneron Links 2026 CEO, CSO PSU Awards to FDA Filings, Approvals and New-Product Revenue Targets Through 2035

Reuters
·
Yesterday

Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone

TIPRANKS
·
Yesterday

Citi Tells Investors It's Time to Sell Moderna After 600%-Plus Stock Gains

Dow Jones
·
Sep 30

Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says

MT Newswires Live
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Ocular Therapeutix (OCUL) and Regeneron (REGN)

TIPRANKS
·
Sep 29

Court Dismisses Regeneron Pharmaceuticals (REGN) Securities Lawsuit Over Eylea and Eylea HD Claims

TIPRANKS
·
Sep 29

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

TIPRANKS
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Regeneron Pharmaceuticals Inc. Stock Falls 4.5%, Underperforms Peers

Dow Jones
·
Sep 29

Ocular Therapeutix Tumbles on Rival Kodiak's Trial Win, Analyst Calls Selloff Overdone

Reuters
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Kodiak Sciences (KOD)

TIPRANKS
·
Sep 29

Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences up 156%

Dow Jones
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Movement Alert|Regeneron Pharmaceuticals Falls 3.52% in Regular Trading, Trading at $760.15

Market Focus
·
Sep 28

Kodiak Sciences Rises After Eye-Disease Drugs Meet Trial Goals

Reuters
·
Sep 28